AzTrials
AzTrials

Recurrent Pregnancy LossNCT06968026

Right Prefrontal Autonomic Mapping in Recurrent Pregnancy Loss With Comorbid Anxiety

A study testing repetitive transcranial magnetic stimulation(rTMS) in people with Recurrent Pregnancy Loss and Anxiety Disorders, run by Shenyang Jinghua Hospital at 4 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Recurrent pregnancy loss is often accompanied by substantial anxiety and may also be associated with autonomic imbalance and increased long-term cardiovascular vulnerability. The present proof-of-concept rTMS-ECG parameter-finding trial will examine whether high-intensity, low-frequency, periodic repetitive… Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Recurrent Pregnancy Loss, Anxiety Disorders
What is being tested?
repetitive transcranial magnetic stimulation(rTMS)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
55 participants
Where
4 sitesChina
Study dates
16 May 2025to 20 Oct 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • 1)Female, aged 18-45 years, and right-handed.
  • 2)Diagnosis of recurrent pregnancy loss (RPL), defined as ≥2 consecutive spontaneous miscarriages before 28 weeks of gestation.
  • 3)Currently non-pregnant, or presenting with a missed abortion (no fetal cardiac activity confirmed by ultrasound).
  • 4)Hamilton Anxiety Rating Scale (HAMA) score ≥14 and Hamilton Depression Rating Scale (HAMD-17) score ≤17 (to exclude clinically significant depression).
  • 5)Diagnosis of generalized anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). The diagnosis will be established through a structured diagnostic interview conducted by a qualified attending-level or senior psychiatrist, either on site or, when on-site assessment cannot be completed, through a secure encrypted video-conferencing platform with multidisciplinary team support.

Who cannot join

  • 1) Contraindications to transcranial magnetic stimulation (TMS), including metallic implants or a history of epilepsy;
  • 2) Uncontrolled blood pressure (systolic >180 mmHg or <90 mmHg);
  • 3) Presence of other major medical conditions, including hyperthyroidism, a history of atrial fibrillation, valvular heart disease, sinus bradycardia, neurological disorders, cerebrovascular disease, or chronic pulmonary disease;
  • 4)Current use of psychotropic medications at the time of screening, to avoid hemodynamic or autonomic confounding;
  • 5) Clinically significant suicide risk;
  • 6) A current or past diagnosis of other psychiatric disorders, including substance use disorders, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium.

Trial locations and contacts

4 sites in 1 country.

China4 sites
  • 242 Hospital Affiliated to Shenyang Medical College

    Shenyang, Liaoning, 110000

  • The Second Affiliated Hospital of Shenyang Medical College

    Shenyang, Liaoning, 110001

  • Shenyang Jinghua Hospital

    Shenyang, Liaoning, China

  • Central Hospital Affiliated to Shenyang Medical College

    Shenyang, Liaoning

Other trials in China

About this study

Official title: Acute Cardiac Autonomic Responses to High-intensity, Low-frequency, Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex in Women With Recurrent Pregnancy Loss and Comorbid Anxiety Disorders: a Proof-of-concept rTMS-ECG Parameter-finding Trial (NEURO-CARD-rTMS-1)

Recurrent pregnancy loss is often accompanied by substantial anxiety and may also be associated with autonomic imbalance and increased long-term cardiovascular vulnerability. The present proof-of-concept rTMS-ECG parameter-finding trial will examine whether high-intensity, low-frequency, periodic repetitive transcranial magnetic stimulation (rTMS) delivered over the right dorsolateral prefrontal cortex can induce detectable acute cardiac autonomic responses in women with recurrent pregnancy loss and comorbid anxiety disorders.

A total of 55 women will be enrolled. During a single experimental session, each participant will undergo a stimulation-intensity sweep protocol with six consecutive stimulation cycles at 100%, 110%, 120%, 130%, 140%, and 150% of resting motor threshold. Each cycle will consist of 40 seconds of 1 Hz stimulation followed by a 20-second rest interval, while electrocardiography will be recorded continuously throughout the procedure. The study will evaluate baseline-corrected heart-rate change, wavelet-derived power near the stimulation-cycle frequency, and the rTMS-induced cardiac coupling index across intensity conditions. The goal is to identify the candidate stimulation intensity that produces the most detectable and physiologically consistent acute cardiac autonomic response for transfer to subsequent NEURO-CARD-rTMS studies.

Read the detailed description

Recurrent pregnancy loss affected approximately 2% to 5% of women of reproductive age and had been associated not only with reproductive burden, but also with substantial psychological distress, including anxiety, depression, and elevated stress. Previous studies further suggested that women with recurrent pregnancy loss could exhibit autonomic dysfunction, greater cardiovascular vulnerability, and altered interactions among emotional regulation, interoception, and autonomic control. The dorsolateral prefrontal cortex, particularly the right dorsolateral prefrontal cortex, had been implicated in anxiety-related functional laterality, threat-related processing, and regulation of stress-related physiological responses. These observations provided the conceptual basis for testing whether inhibitory low-frequency stimulation over the right dorsolateral prefrontal cortex could induce measurable acute cardiac autonomic responses in women with recurrent pregnancy loss and comorbid anxiety disorders.

The present study, NEURO-CARD-rTMS-1, will be conducted as a proof-of-concept rTMS-ECG parameter-finding clinical trial using a within-subject, single-factor repeated-measures design. Fifty-five consecutive women with recurrent pregnancy loss and comorbid anxiety disorders will be enrolled. Eligible participants will be women aged 18 to 45 years who are right-handed, meet the predefined diagnostic criteria for recurrent pregnancy loss, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for an anxiety disorder, have a Hamilton Anxiety Rating Scale score of 14 or higher, and do not have clinically significant depressive symptoms. Individuals with contraindications to transcranial magnetic stimulation, major medical conditions that may affect cardiac autonomic function or increase procedural risk, current psychotropic medication use, clinically significant suicide risk, or major psychiatric disorders other than anxiety disorders will be excluded.

Each participant will undergo a stimulation-intensity sweep protocol targeting the right dorsolateral prefrontal cortex. Resting motor threshold will first be determined over the right primary motor cortex. The scalp target for repetitive transcranial magnetic stimulation will then be localized using the mirrored adjusted BeamF3/F4 method, and the coil will be oriented at 45 degrees to the sagittal plane with the handle pointing posteriorly. After a 20-second prestimulation resting baseline, six consecutive stimulation cycles will be delivered at increasing intensities from 100% to 150% of resting motor threshold, in 10% increments. Each cycle will consist of a 40-second stimulation period delivered at 1 Hz, followed by a 20-second rest interval, thereby forming a 60-second stimulation-locked cycle. The maximum stimulation intensity will not exceed 85% of maximum stimulator output. Continuous electrocardiography will be recorded throughout the full procedure.

The primary outcome will be baseline-corrected heart-rate change across stimulation intensity conditions, defined as decreased HR. Within each stimulation cycle, the mean heart rate during the 10 seconds immediately before stimulation onset will serve as the baseline, and the mean heart-rate change during the subsequent 40-second stimulation period will be calculated relative to this baseline. More negative values will indicate greater heart-rate reduction induced by the corresponding stimulation intensity. The first secondary outcome will be mean normalized wavelet power near the frequency of the 60-second stimulation cycle, corresponding to approximately 0.0167 Hz, with the Morlet wavelet used for the primary spectral analysis. The second secondary outcome will be the rTMS-induced cardiac coupling index at each stimulation intensity, defined as the Pearson correlation across participants between decreased HR and mean normalized wavelet power near the frequency of the 60-second stimulation cycle. Safety outcomes will include non-serious adverse events and serious adverse events occurring during the procedure or during the 1-hour post-procedure observation period.

The study will test whether a high-intensity, low-frequency, periodic repetitive transcranial magnetic stimulation strategy applied over the right dorsolateral prefrontal cortex can induce a detectable acute cardiac autonomic response under a threshold-reference framework. The study will also identify the candidate stimulation intensity that optimizes detectability and physiological consistency, based on the joint characterization of heart-rate change, stimulation-cycle-frequency power, and the rTMS-induced cardiac coupling index. The outputs of this study are intended to provide a methodological and parameter basis for subsequent NEURO-CARD-rTMS studies with fixed stimulation parameters, larger samples, and longer-term follow-up.

Being tested
repetitive transcranial magnetic stimulation(rTMS)
Keywords
Recurrent pregnancy loss, anxiety disorders, repetitive transcranial magnetic stimulation, dorsolateral prefrontal cortex, autonomic modulation
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • repetitive transcranial magnetic stimulation(rTMS)Device

    Participants will undergo a right DLPFC rTMS intensity-sweep protocol with simultaneous electrocardiography (ECG) recording. After a 20 s prestimulation resting baseline, six consecutive stimulation cycles will be delivered at 100%, 110%, 120%, 130%, 140%, and 150% of individual resting motor threshold (RMT). Each cycle will consist of 40 s of 1 Hz stimulation followed by a 20 s intertrain interval, forming a 60 s stimulation-locked cycle. The maximum stimulation intensity will not exceed 85% of maximum stimulator output.

Study groups in NCT06968026
Study groupRoleWhat they receive
Right DLPFC rTMS-ECG intensity-sweep protocolExperimentalSingle-group, within-subject, repeated-measures proof-of-concept trial. Eligible participants will undergo one right dorsolateral prefrontal cortex (DLPFC) rTMS-ECG intensity-sweep session consisting of six consecutive stimulation cycles delivered sequentially from 100% to 150% of resting motor threshold (RMT) in 10% increments. Each cycle will include 40 s of 1 Hz stimulation followed by a 20 s intertrain interval. Continuous ECG will be recorded throughout the procedure.
Receives: Device: repetitive transcranial magnetic stimulation(rTMS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Baseline-corrected heart-rate change across stimulation intensity conditions

    decreased HR will be calculated separately for each stimulation intensity condition to assess the acute cardiac autonomic response induced by escalating low-frequency repetitive transcranial magnetic stimulation (rTMS) over the right dorsolateral prefrontal cortex (DLPFC). Within each stimulation cycle, the mean heart rate during the 10 s immediately before stimulation onset will be used as the baseline, and the mean heart-rate change during the subsequent 40 s stimulation period will be calculated relative to this baseline. More negative values will indicate greater heart-rate reduction induced by the corresponding stimulation intensity. The primary analysis will compare decreased HR across the six intensity conditions, 100%, 110%, 120%, 130%, 140%, and 150% resting motor threshold (RMT), with 100% RMT serving as the within-subject threshold-reference condition.

    Measured: Day 1

Secondary outcomes (4)
  1. Mean normalized wavelet power near the frequency of the 60-s stimulation cycle (0.016-0.017 Hz)

    The primary spectral analysis will use the Morlet wavelet to extract mean normalized wavelet power near the frequency of the 60-s stimulation cycle (0.016-0.017 Hz) from the ECG-derived R-R interval time series and to compare this measure across the six stimulation intensity conditions. This outcome will be used to assess whether ECG dynamics show a response near the frequency of the 60-s stimulation cycle and will not be used as evidence of strict physiological entrainment.

    Measured: Day 1

  2. rTMS-induced cardiac coupling index at each stimulation intensity

    At each stimulation intensity, the rTMS-induced cardiac coupling index will be defined as the Pearson correlation coefficient across participants between decreased HR and mean normalized wavelet power near the frequency of the 60-s stimulation cycle (0.016-0.017 Hz). This index will quantify the consistency between directional heart-rate change and power aggregation near the frequency of the 60-s stimulation cycle across stimulation intensities. Because heart-rate reduction will be represented by more negative decreased HR values and power aggregation near the frequency of the 60-s stimulation cycle will be represented by higher normalized power values, an intensity condition in which participants with greater heart-rate reduction also show higher power near the frequency of the 60-s stimulation cycle will produce a negative correlation pattern. This index will be used as a parameter-level quantitative measure and will not be interpreted as direct evidence of strict physiological entr

    Measured: Day 1

  3. Incidence of non-serious adverse events

    The study will record pain at the stimulation site, transient facial muscle contractions, headache, dizziness, presyncope, other participant-reported discomfort, and other investigator-observed non-serious adverse events.

    Measured: Day 1

  4. Incidence of serious adverse events

    The study will record serious adverse events occurring during the procedure or during the post-procedure observation period, including syncope, seizure, and any other event requiring medical intervention or leading to termination of the study procedure.

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 May 2025
  2. Study start16 May 2025
  3. Primary completion20 Oct 2025
  4. Study completion20 Oct 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single-group, within-subject, repeated-measures parameter-finding study. All participants will undergo the same right DLPFC rTMS-ECG intensity-sweep protocol, consisting of six consecutive stimulation cycles delivered sequentially from 100% to 150% of resting motor threshold in 10% increments. Each cycle will include 40 s of 1 Hz stimulation followed by a 20 s intertrain interval.
Masking
None (open label)
Enrolment
55 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06968026
Sponsor's protocol ID
2025-0522_V2
Status last verified
May 2025
First submitted
3 May 2025
Last updated
7 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The study protocol, analysis scripts, and supporting materials, will be made available at the time of publication of the final article. Requests for additional materials or clarifications may be directed to the corresponding author.

Questions about this trial

What is this clinical trial studying?

A study testing repetitive transcranial magnetic stimulation(rTMS) in people with Recurrent Pregnancy Loss and Anxiety Disorders, run by Shenyang Jinghua Hospital at 4 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Baseline-corrected heart-rate change across stimulation intensity conditions (time frame: Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in